Salvage of the retinal ganglion cells in transition phase in Alzheimer’s disease with topical coenzyme Q10: is it possible?
The evaluation of the short-term effect of topically applied coenzyme Q10 (CoQ10) on retina and choroid in Alzheimer’s disease (AD) was aimed in this study.
Randomized controlled study included a total of 93 patients, 62 of whom with AD. Thirty (32.3%) AD patients received treatment (Group 1), 32 (34.4%) AD patients observed without treatment (Group 2), and Group 3 included 31 (33.3%) healthy controls (HC). Neurological and ophthalmological examinations including optical coherence tomography (OCT) were executed.
Retinal nerve fiber layer (RNFL) thickness in all quadrants increased following CoQ10 treatment in Group 1; however significant rise yielded in average and temporal quadrant RNFL thickness. Average and superonasal sector ganglion cell-inner plexiform layer (GCIPL) thickness increased significantly following CoQ10 treatment. The correlation analysis between difference in pre- and posttreatment OCT values in Group 1 revealed that rise in average RNFL thickness was inversely correlated with duration of the disease and rise in average GCIPL thickness and superonasal sector thickness was inversely correlated with severity of the disease.
Short-term topical CoQ10 resulted in improvement in AD related retinal ganglion cell (RGC) loss which may reflect the salvage of some RGCs in the reversible transitional phase. More bioavailability through intravitreal route of administration and longer duration of effect with sustained release forms may possibly help enhalting the RGC loss, especially incipience of neurodegenerative diseases.
KeywordsAlzheimer’s disease Coenzyme Q10 Neurodegeneration Optical coherence tomography
Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work: Refika Hande Karakahya, Tuba Şaziye Özcan
Drafting the work or revising it critically for important intellectual content: Tuba Şaziye Özcan
Final approval of the version to be published: Refika Hande Karakahya, Tuba Şaziye Özcan
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict(s) of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ordu University Ethical Committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Statement of informed consent
Informed consent was obtained from all individual participants included in the study.
- 3.Jack CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC et al (2011) Introduction to the recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement J Alzheimer’s Assoc 7:257–262CrossRefGoogle Scholar
- 4.McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:263–269CrossRefGoogle Scholar
- 11.Cunha JP, Proença R, Dias-Santos A, Melancia D, Almeida R, Águas H et al (2017) Choroidal thinning: Alzheimer's disease and aging. Alzheimers Dement 30:11–17Google Scholar
- 16.den Haan J, Verbraak FD, Visser PJ, Bouwman FH (2017) Retinal thickness in Alzheimer’s disease: a systematic review and meta-analysis. Alzheimers Dement 6:162–170Google Scholar
- 18.Cunha LP, Lopes LC, Costa-Cunha LV, Costa CF, Pires LA, Almeida AL et al (2016) Macular thickness measurements with frequency domain-OCT for quantification of retinal neural loss and its correlation with cognitive impairment in Alzheimer’s disease. PLoS One. https://doi.org/10.1371/journal.pone.0153830 CrossRefGoogle Scholar
- 26.Williams MA, Mcgowan AJ, Cardwell CR, Cheung CY, Craig D, Passmore P (2015) Retinal microvascular network attenuation in Alzheimer's disease. Alzheimers Dement 1:229–235Google Scholar
- 28.Ajith TA (2013) Mitochondria: oxidative stress, dysfunction and cell death. VNT Biol Med Chem 1:21–32Google Scholar
- 33.Feher J, Kovacs B, Kovacs I, Schveoller M, Papale A, Balacco Gabrieli C (2015) Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-l-carnitine, n-3 fatty acids, and coenzyme Q10. Int J Ophthalmol 219:154–166Google Scholar
- 35.Fato R, Bergamini C, Leoni S, Pinna A, Carta F, Cardascia N et al (2010) Coenzyme Q10 vitreous levels after administration of coenzyme Q10 eyedrops in patients undergoing vitrectomy. Acta Ophthalmol. https://doi.org/10.1111/j.1755-3768.2009.01632
- 37.Banitt MR, Ventura LM, Feuer WJ, Savatovsky E, Luna G, Shif O et al (2013) Progressive loss of retinal ganglion cell function precedes structural loss by several years in glaucoma suspects. Invest Ophthalmol Vis Sci. https://doi.org/10.1167/iovs.12-11